International sales gain for PUR Biologics
PUR Biologics’ robust distribution channels appear to be expanding sales worldwide
October 24, 2023, Irvine, CA., / OrthoSpineNews / – Following a successful participation at the North American Spine Society (NASS) conference, healthcare technology company HippoFi, Inc. (OTC: ORHB) announced that its wholly owned subsidiary, PUR Biologics, has expanded its sales to include several notable global healthcare institutions.
Ryan Fernan, Head of PUR Biologics, said: “Our recent collaborations with ZIMMER BIOMET and Italian company BPB Medica have attracted wider international attention. It is encouraging to see our spinal biologics expertise and innovation gaining global recognition.”
CJ Wiggins, Executive Chairman and CEO of HippoFi, added: “The strength of our distribution channels is a core component of our company design and provides us with deep coverage and a source of revenue opportunities for our spinal biologics.”
With PUR Biologics’ clear leadership trajectory in the biotech sector, there is incredible momentum building.
For more information about PUR Biologics’ full line of biological products, visit www.PURbiologics.com.
__________
About PUR Biologics
PUR Biologics, a wholly owned subsidiary of HippoFi, Inc. (OTC PINK: ORHB), is a leading biologics company committed to supporting surgeons and hospitals in providing the best care to their patients. PUR Biologics’ full line of biological products currently includes: advanced allografts and demineralized extracellular matrices (d-ECM), innovative synthetic solutions, cellular-derived tissues, and a future of next-generation regenerative stem cell and growth factor-driven therapies for the treatment of osteoarthritis and cartilage. regeneration.
About HippoFi, Inc.
HippoFi, Inc. delivers its breakthrough healthcare innovations through an extensive sales channel network while deploying first-to-market solutions in the multi-billion dollar biotech, fintech and artificial intelligence (AI) markets. HippoFi consists of three segments: Regenerative Therapeutics, Digital Payments and AI, which use the same customer channels to commercialize solutions, increase revenue and improve patient outcomes.
HippoFi, Inc. is publicly traded under the symbol: ORHB and is headquartered in Irvine, California. For more information, please visit: www.HippoFi.com and www.PURbiologics.com.
Contact
HippoFi, Inc.
949-323-2330
info@hippofi.com
